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Abstract The incidence of human papillomavirus (HPV)–
associated anal cancer in men who have sex with men (MSM)
is striking and has not been mitigated by the use of highly
active antiretroviral therapy. Detection and treatment of high-
grade anal intraepithelial neoplasia (HGAIN) may reduce the
incidence of anal cancer. Anal cytology is a useful tool to
detect HGAIN; annual screening of HIV-positive MSM and
biennial screening of HIV-negative MSM appears to be cost-
effective. MSMwith abnormal cytology should be referred for
high-resolution anoscopy and biopsy. Individuals with
HGAIN should receive treatment; treatment modalities for
HGAIN demonstrate moderate efficacy and are usually well
tolerated, but greater study is required to determine which
treatment is optimal. Large prospective studies are needed to
document the efficacy of screening and treatment of HGAIN
on anal cancer incidence. The HPV vaccine holds promise for
primary prevention of anal cancer in MSM, but significant
implementation challenges remain.
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Introduction
Anal cancer occurs at alarming rates in HIV-positive and
HIV-negative men who have sex with men (MSM)
compared with the general population. According to recent
data from the United States and Europe, the incidence of
anal cancer among HIV-positive individuals ranges from 42
to 137 cases per 100,000 person-years, a rate that is 30 to
100 times higher than that of the general population [1••,
2••, 3••, 4••, 5]. Even before the HIV epidemic, anal cancer
incidence among MSM was estimated to be as high as
about 35 cases per 100,000 person-years, which is
comparable to the incidence of cervical cancer in the
United States before the advent of routine cervical cytology
screening [6]. Anal cancer pathogenesis is similar to that of
cervical cancer, including a causative association with the
human papillomavirus (HPV) [7•]. Persistence of oncogen-
ic HPV infection is thought be a necessary factor in the
development of anal cancer and high-grade anal intra-
epithelial neoplasia (HGAIN), the putative anal cancer
precursor.
Unlike cervical HPV infection, which peaks in the third
decade in women, anal HPV infection is highly prevalent
throughout adult life among MSM well into the sixth
decade [8, 9]. Among HIV-positive MSM, the prevalence
of anal HPV infection ranges between 72% and 90%,
whereas among HIV-negative MSM, the prevalence ranges
from 57% to 61% [10, 11••]. Consistent with the high
prevalence of anal HPV infection, HGAIN is highly
pervasive among HIV-positive MSM, with a prevalence of
43% to 52% and an incidence of 49% over 4 years [12, 13].
Though less widespread, HGAIN among HIV-negative
MSM is still substantial, with a prevalence of 25% and
incidence of 17% over 4 years [11••, 12].
If left untreated, HGAIN has demonstrated potential for
malignant transformation [14, 15]. Even with surveillance
and treatment of HGAIN, malignancy can develop, espe-
cially in immunosupressed individuals with extensive
disease [16]. In HIV-positive individuals, restoration of
immune function such as that afforded by highly active
antiretroviral therapy (HAART) has not demonstrated
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substantial benefit in reducing incidence of HGAIN or
regression of existing high-grade lesions [2••, 17]. Several
studies have demonstrated a higher incidence of anal cancer
since the introduction of HAART compared with the pre-
HAART era [1••, 18]. This may be attributable to increased
survival on HAART allowing HIV-positive individuals to
live with oncogenic HPV infection long enough to develop
HGAIN and anal cancer.
Screening
The goal of anal cancer screening is similar to that of
cervical cancer screening, namely, to identify and treat
HGAIN before the development of cancer. Cytology is the
primary screening tool for detection of HPV-associated
disease in the anus. The cytology technique is simple and
can easily be performed in the context of an office visit.
Although anal cytology is typically performed by clini-
cians, patient self-collected anal cytology has also been
evaluated. Self-collected specimens offer the advantage of
convenience and privacy, are acceptable to patients, and
have been used for rectal specimens to screen for other
sexually transmitted diseases [19]. Though specimen
adequacy rates for cytology are slightly lower for self-
collected samples, sensitivity for detection of anal intra-
epithelial neoplasia (AIN) is comparable [11••, 20].
Samples that are inadequate because of scant cellularity
may also be repeated.
To perform cytology, a rayon or polyester swab is first
moistened with tap water and then inserted blindly as far as
possible, with gentle pressure and rotation until it reaches
the entire rectum. Synthetic fiber swabs are preferred over
cotton because cells cling to cotton, decreasing cellular
yield. The swab is then rotated 360 degrees while gentle
pressure is applied to the walls of the anal canal as the swab
is gradually withdrawn. The swab can then be placed in
liquid cytology media or smeared on a glass slide
(conventional cytology). Both liquid-based and convention-
al cytology are acceptable modalities with similar cellular
yield and adequacy rates [21].
Anal cytology is categorized according to the Bethesda
system for cervical cytology: normal, atypical squamous
cells of undetermined significance—ASC-US, low-grade
squamous intraepithelial lesion—LSIL, high-grade squa-
mous intraepithelial lesion—HSIL, atypical squamous cells,
cannot rule out HSIL—ASC-H [22]. Anal histology is
graded according to severity; mild abnormalities are graded
as AIN I, and moderate to severe abnormalities are graded
as AIN II or AIN III (HGAIN). Although a cytologic
diagnosis of HSIL is nearly always associated with HGAIN
diagnosed on biopsy, HGAIN is also frequently associated
with mildly abnormal cytologic diagnoses (ASC-US, LSIL)
[23]. Therefore, we recommend that individuals with
abnormal cytology findings of ASCUS or worse be referred
for high-resolution anoscopy (HRA) with biopsy. Individ-
uals with HGAIN on biopsy should subsequently be treated
(Fig. 1).
If resources for HRA are limited, then cytology can be
used for triage: patients with HSIL or ASC-H cytology
should be prioritized for HRA, followed by patients with
LSIL, and finally by those with ASC-US. Cytology can
also be useful as a quality control measure for the
anoscopist, because individuals with HSIL on cytology
should have HGAIN on biopsy. If no AIN or only low-
grade AIN is detected in an individual with HSIL cytology,
we recommend repeat HRA to ensure the high-grade lesion
was not missed.
Cytology
Normal ASC-US
No lesion seen
LSIL
Anoscopy with
biopsy
AIN I
Follow-up in 6
months or treat if
minimal potential
for morbidity
AIN II or III
Treat
Repeat in 12
months (HIV+)
Repeat in 2–3
years (HIV–)
HSIL (or ASC-H)
Fig. 1 Protocol for screening of
anal intraepithelial neoplasia
(AIN). ASC-H—atypical
squamous cells, cannot rule out
HSIL; ASC-US—atypical squa-
mous cells of undetermined sig-
nificance; HSIL—high-grade
squamous intraepithelial lesion;
LSIL—low-grade squamous
intraepithelial lesion
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Multiple studies have examined the operating character-
istics of anal cytology. The reported sensitivity to detect
AIN on HRA among different high-risk populations
(including HIV-positive MSM) is between 69% and 93%,
with specificity ranging from 32% to 64% [24]. Among
HIV-negative MSM, cytology is generally less sensitive but
more specific than in HIV-positive MSM, with sensitivity
reported as about 50% to 60% and specificity of 76% to
84% [11••, 25]. The predictive value of cytology can be
improved through repeated testing; in a large, prospective,
cohort study by Palefsky et al. [26], the positive predictive
value of cytology improved from 38% to 78% and the
negative predictive value improved from 46% to 79% after
consecutive testing for 2 years.
Although cervical HPV testing is regularly used as an
adjunct to triage women with mildly abnormal cervical
cytology test results, the role of anal HPV testing as an
adjunct to anal cytology is unclear. Based on limited data, it
appears that in HIV-positive MSM, using HPV testing as an
adjunct to cytology for detection of HGAIN is highly
sensitive but has poor specificity and poor positive
predictive value [27]. HPV testing may be more useful in
HIV-negative MSM, because the presence of oncogenic
HPV infection, especially HPV-16, is highly specific for
HGAIN on biopsy [25•]. HPV testing may also be useful
among populations with a lower prevalence of anal HPV
infection than HIV-positive MSM (eg, HIV-negative MSM)
for its negative predictive value.
Because of the high prevalence of AIN in certain
populations, some researchers have advocated foregoing
cytology and using HRA as a primary screening test. This
consideration is reasonable, given that a single negative
cytology result has a poor negative predictive value in
populations with a high prevalence of disease (eg, HIV-
positive MSM). However, given the insufficient availability
of HRA, we believe that use of cytology to triage
individuals to HRA and biopsy is the appropriate approach
to AIN or anal cancer screening in most settings.
Currently, no national consensus exists on an optimal
method and frequency for anal cancer screening. Guidelines
from the Centers for Disease Control and Prevention
acknowledge that cytology is used by many experts to
screen for AIN in HIV-positive individuals [28••]. Screen-
ing HIV-positive MSM annually and screening HIV-
negative MSM every 2 years appears to be cost-effective,
with a cost of about $16,000 per quality-adjusted life year
(QALY) saved; this is comparable to other commonly used
preventive health measures [29, 30]. However, modeling
studies conducted under different assumptions in the United
Kingdom demonstrate much higher costs per QALY for
MSM, thus the issue of cost efficacy must be analyzed
separately in health care systems where screening may be
used [31].
An important caveat regarding our recommendation for
anal cytology screening is that screening should only be
instituted if treatment is available for individuals with
HGAIN. If expertise is not available to perform HRA and
treat HGAIN, then, at a minimum, high-risk patients should
receive an annual digital rectal exam (DRE) to feel for
masses in the anal canal. Although no data exist on the
performance of DRE in detecting anal cancer, DRE is easy
to perform and offers the potential benefit of detecting anal
cancers at an early and treatable stage.
Diagnosis
HRA is typically performed in an outpatient setting using
techniques similar to those of cervical colposcopy. After
insertion of an anoscope and the application of 3% acetic
acid with or without Lugol’s iodine, the transformation
zone between rectal columnar and anal squamous epitheli-
um, up to and including the perianal epithelium, is
visualized under magnification, and abnormal areas are
biopsied. Local anesthesia is usually not required to
perform biopsy unless the lesion is perianal or close to the
anal verge.
Although HRA-guided biopsy is the gold standard for
diagnosis of HGAIN, like cervical colposcopy, the perfor-
mance of HRA as a diagnostic test is dependent on operator
ability to visualize and properly perform biopsy of lesions.
In our experience, a significant and lengthy learning curve
exists for developing competence in HRA. No large studies
have been conducted on the magnitude of interobserver
variability associated with this technique.
Our institution is committed to addressing the current
shortage of HRA providers by educating and training
providers in HRA techniques. Courses in HRA are
provided by clinician-investigators from our institution in
collaboration with American Society of Colposcopy and
Cervical Pathology. HRA can be performed by any
clinician who cares for at-risk patients, including advance
practice clinicians, primary care and specialist physicians
(ie, dermatology, infectious disease, oncology), and sur-
geons. Clinicians may also receive advanced training and
experience at the University of California San Francisco
Anal Neoplasia Clinic.
Current Treatment Modalities
AIN treatment can be challenging because recurrence after
treatment and development of metachronous lesions (con-
current separate lesions) is common. There are no random-
ized controlled trials of AIN treatments to inform treatment
recommendations, thus selection of treatment modality is
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directed not only by the extent and location of disease but
also by available expertise and resources. Treatment of AIN
generally falls into three categories: local treatment with
clinician or patient-applied creams and liquids, clinician-
applied ablative techniques such as electrocautery, carbon
dioxide (CO2) laser, infrared coagulation (IRC; Redfield
Corporation, Rochelle Park, NJ), and surgery. The advan-
tages and disadvantages of these approaches are listed in
Table 1. Although complications are uncommon, patients
should be counseled that ablative and surgical therapies
may be associated with side effects such as painful
defecation, abscess formation, anal stenosis, incontinence,
and scarring/disfiguration.
We generally recommend treatment for HGAIN except
in situations of extensive circumferential disease where
morbidity from treatment may outweigh benefit. One
treatment approach under study for diffuse disease includes
use of 5-fluorouracil cream to reduce the extent of disease,
which may then lend itself to focal therapy with IRC [32].
Extensive disease that includes both HGAIN and low-grade
AIN (LGAIN) can be addressed by focusing treatment on
areas of HGAIN. Extensive HGAIN is more common and
more difficult to eradicate in HIV-positive MSM, but
successful treatment is possible with use of surgery
followed by IRC [33••]. Although the malignant potential
of LGAIN (AIN I) is unknown, AIN I has the potential to
Table 1 Treatments for perianal and intra-anal intraepithelial neoplasia
Treatment modality Efficacy
data
Advantages Disadvantages
Topical treatments
85% trichloroacetic acid
(TCA)
X Inexpensive May lead to scarring
Office-based pain usually shortlived and
relatively mild
Multiple visits may be needed
More effective for limited disease
Liquid nitrogen Inexpensive May lead to scarring
Office-based pain usually shortlived and
relatively mild
Multiple visits may be needed
More effective for limited disease
Imiquimod X Patient-applied Pain/irritation
Multiple visits may be needed
Patients may miss small lesions
May be less efficacious in HIV-positive individuals
Approved only for perianal lesions
Approved only for condyloma
Ablative therapies
Infrared coagulation X Office-based Pain
Can treat extensive disease Bleeding
Infection
Electrocautery May be office-based Pain
Inexpensive Bleeding
Infection
CO2 laser X May be office-based Pain
Can treat extensive disease Bleeding
Infection
Generates smoke “plume” that requires
evacuation
Surgical excision Used to treat extensive disease Requires surgical setting
Pain
Bleeding
Infection
Relatively expensive compared with other
therapies
X—Designates therapy shown to be potentially effective in retrospective studies or open-label trials.
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progress to HGAIN [12]. Therefore, if treatment for
HGAIN is undertaken, it is advisable to treat adjacent
LGAIN as well if the lesions can be treated without
excessive morbidity. In addition, it is appropriate to treat
individuals with LGAIN who manifest symptoms such as
pain or pruritus.
For small lesions (<1 cm2) located in the perianal or
intra-anal region, there are several topical treatment options.
Multiple treatment sessions are often necessary, but these
therapies are generally well tolerated. Trichloroacetic acid
was effective in treating intra-anal HGAIN in a small series
of HIV-positive and HIV-negative MSM and appeared most
effective in individuals with limited disease (fewer than two
lesions) [34•]. Perianal and intra-anal disease can also be
treated with liquid nitrogen. Imiquimod has also been used
in small open-label studies in Europe and shows promise
for treatment of intra-anal HGAIN [35]. In long-term
follow-up (30 months) 14 of 19 (74%) treated patients
remained clear of AIN at the originally treated site, whereas
4 of 19 developed recurrence of HGAIN at the original site
and more than 50% developed HGAIN at a different site
[36•]. Although encouraging, these results have not been
successfully replicated by North American groups and
further study is needed.
For larger lesions, ablative therapies including IRC, CO2
laser, and electrocautery are usually warranted. IRC is an
office-based procedure and offers an advantage over
electrocautery because no smoke is created. Several
retrospective studies and a phase 1 safety study indicate
that IRC is well tolerated and is about 65% effective at
treating an individual HGAIN lesion in HIV-positive MSM,
with even better efficacy (81% for a single lesion) in HIV-
negative MSM [37, 38•, 39]. One retrospective study
conducted primarily in MSM used CO2 laser alone or in
combination with surgical excision and/or imiquimod and
found that 65% of patients were completely disease free at
12 months [40]. Because of the use of multiple treatment
modalities, it is difficult to infer the independent effect of
CO2 laser. No published studies have described the efficacy
of electrocautery.
Surgical destruction is usually reserved for individuals
with extensive disease who require an examination under
anesthesia and multiple biopsies to rule out invasive cancer.
In a large retrospective study of surgical treatment followed
by repeated office-based procedures to treat recurrent
disease, a high resolution rate at 36 months was achieved
(86%) [33••].
Follow-up and Surveillance after Treatment
No consensus exists about optimal frequency of follow-up
and surveillance after treatment of AIN with surgical or
ablative techniques. At our institution, individuals are seen
for repeat anoscopic evaluation as soon as they are able to
tolerate examination, typically within 2 months post-
treatment. If further small pockets of disease are found,
they can often be treated topically as described above. If no
further evidence of disease is found, the patient can then
return for HRA in 6 to 12 months.
For individuals with untreated HGAIN (eg, patients with
contraindications to treatment or disease too extensive to
treat), we recommend close monitoring with repeat clinical
evaluation and HRA every 3 to 4 months to search for any
signs of progression to cancer (eg, pain, bleeding, ulceration).
Frequent evaluation is imperative so that if anal cancer occurs,
it is detected at an early and highly curable stage.
The Promise of Prevention
Given that at a largemajority of anal cancers are attributable to
HPV-16 (∼72%), the implications are enormous for HPV
vaccination as a primary prevention tool to prevent AIN and
anal cancer [7•]. The quadrivalent vaccine against HPV types
6, 11, 16, and 18 was demonstrated to be safe and effective
in preventing genital warts and persistent HPV infection in
males as well as preventing cervical and genital cancer
precursor lesions in females [41, 42]. Data regarding vaccine
efficacy to prevent AIN are forthcoming. Currently, the
vaccine is licensed for males between the ages of 9 and
26 years for the prevention of warts. Though the efficacy of
the vaccine against persistent HPV infection implies that it
would also be effective at preventing anal cancers attribut-
able to HPV 16 and 18, the vaccine’s efficacy against AIN
and anal cancer will depend on the timing of vaccination and
the levels of penetration achieved in the target population of
MSM. If only low levels of vaccination are achieved or
vaccination primarily occurs after the acquisition of anal
HPV, then the vaccine may not have a great impact on anal
cancer incidence in MSM.
Although the recent licensure of the quadrivalent HPV
vaccine for boys heralds an era of opportunity for
prevention of anal cancer in MSM, numerous challenges
may prevent the vaccine from achieving high levels of
penetration in the male population. First, the vaccine is
costly, and cost-efficacy studies have suggested that
vaccination of males to prevent cervical cancer in females
would not be cost efficient if high levels of coverage were
achieved in the female population [43]. As of 2008,
vaccination coverage in the US female population ranging
in age from 13 to 17 years (37% received ≥ one dose, 18%
received all three doses) is much lower than that used in the
above cost-efficacy model, so vaccination of males is likely
more cost-effective than current estimates suggest [44].
Furthermore, these analyses did not take into account the
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vaccine’s potential impact on anal cancer among MSM, a
factor that should be considered in deciding whether
vaccination of males is warranted. Another issue is that
the vaccine is most effective in HPV-naïve individuals, so
that ideally males should be targeted for vaccination prior
to sexual debut. Identifying young MSM at risk for anal
cancer prior to sexual debut would be challenging, if not
impossible. Therefore, if the HPV vaccine is to be effective
in decreasing anal cancer in MSM, universal vaccination of
preadolescent males would likely be necessary.
Conclusions
Of foremost interest for future study is whether detection and
treatment of HGAIN ultimately reduces anal cancer incidence.
A randomized, controlled trial would provide definitive
evidence for the efficacy of anal cancer screening. Anal HPV
infection may also have public health implications beyond
anal cancer because recent data have demonstrated that
infection with multiple HPV types is independently associated
with acquisition of HIV infection among MSM [45•]. A link
between sexually transmitted infections and increased sus-
ceptibility to HIV infection has been established over the past
decade; however, interventions to treat or prevent sexually
transmitted infections to reduce HIV acquisition have
generally been disappointing [46]. The possible role that
anal HPV infection might play in HIV acquisition certainly
warrants further investigation, especially given the availabil-
ity of a highly efficacious vaccine against HPV infection.
Disclosure No potential conflict of interest relevant to this article
was reported.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Papers of particular interest, published recently,
have been highlighted as:
• Of importance
•• Of major importance
1. •• Piketty C, Selinger-Leneman H, Grabar S, et al.: Marked
increase in the incidence of invasive anal cancer among HIV-
infected patients despite treatment with combination antiretroviral
therapy. AIDS 2008, 22:1203–1211. The incidence of anal cancer
was 75 per 100,000 person-years among HIV-positive MSM in the
French Hospital Database on HIV and increased from the pre-
HAART era to the post-HAART era.
2. •• Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA:
Risk of human papillomavirus-associated cancers among
persons with AIDS. J Natl Cancer Inst 2009, 101:1120–1130.
Linking AIDS and cancer registry data from 15 US states, this
study showed the incidence of anal cancer increased 104% from
the pre-HAART era to the post-HAART era (20.7 cases vs 42.3
cases /100,000 person-years).
3. •• D’Souza G, Wiley DJ, Li X, et al.: Incidence and epidemiology
of anal cancer in the multicenter AIDS cohort study. J Acquir
Immune Defic Syndr 2008, 48:491–499. The incidence of anal
cancer in the US multicenter AIDS cohort study was 137/100,000
person-years among HIV-positive MSM since 1996.
4. •• Patel P, Hanson DL, Sullivan PS, et al.: Incidence of types
of cancer among HIV-infected persons compared with the
general population in the United States, 1992–2003. Ann
Intern Med 2008, 148:728–736. Matching data from the Adult
and Adolescent Spectrum of HIV Disease Project, the HIV
Outpatient Study and the Surveillence, Epidemiology, and End
Results Program, this study showed that the incidence of anal
cancer in HIV-positive MSM was 78 per 100,000 person-years
since 2000.
5. Joseph DA, Miller JW, Wu X, et al.: Understanding the burden of
human papillomavirus-associated anal cancers in the US. Cancer
2008, 113(10 Suppl):2892–2900.
6. Daling JR, Weiss NS, Hislop TG, et al.: Sexual practices, sexually
transmitted diseases, and the incidence of anal cancer. N Engl J
Med 1987, 317:973–977.
7. • Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human
papillomavirus type distribution in anal cancer and anal
intraepithelial lesions. Int J Cancer 2009, 124:2375–2383. This
meta-analysis describes the prevalence and type distribution of
HPV in 992 cases of invasive anal cancer—472 HSIL cases and
360 LSIL cases. HPV prevalence was 71%, 91%, and 88%,
respectively. HPV 16 or HPV 18 were present in 72% of anal
cancers.
8. Schiffman M, Kjaer SK: Chapter 2: Natural history of anogenital
human papillomavirus infection and neoplasia. J Natl Cancer Inst
Monogr 2003, 31:14–19.
9. Chin-Hong PV, Vittinghoff E, Cranston RD, et al.: Age-specific
prevalence of anal human papillomavirus infection in HIV-
negative sexually active men who have sex with men: the
EXPLORE study. J Infect Dis 2004, 190:2070–2076.
10. Palefsky JM, Holly EA, Ralston ML, Jay N: Prevalence and risk
factors for human papillomavirus infection of the anal canal in
human immunodeficiency virus (HIV)-positive and HIV-negative
homosexual men. J Infect Dis 1998, 177:361–367.
11. •• Chin-Hong PV, Berry JM, Cheng SC, et al.: Comparison of
patient- and clinician-collected anal cytology samples to screen for
human papillomavirus-associated anal intraepithelial neoplasia in
men who have sex with men. Ann Intern Med 2008, 149: 300–
306. This population-based study of HIV-positive and HIV-
negative MSM in San Francisco, California demonstrated that
the prevalence of HGAIN was 43% in HIV-positive and 25% in
HIV-negative MSM. Self-collected anal cytology demonstrated
similar sensitivity for detection of AIN compared with clinician-
collected samples.
12. Palefsky JM, Holly EA, Ralston ML, et al.: High incidence of anal
high-grade squamous intra-epithelial lesions among HIV-positive
and HIV-negative homosexual and bisexual men. AIDS 1998,
12:495–503.
13. Palefsky JM, Holly EA, Efirdc JT, et al.: Anal intraepithelial
neoplasia in the highly active antiretroviral therapy era among HIV-
positive men who have sex with men. AIDS 2005, 19:1407–1414.
14. Devaraj B, Cosman BC: Expectant management of anal squamous
dysplasia in patients with HIV. Dis Colon Rectum 2006, 49:36–40.
Curr Infect Dis Rep (2010) 12:126–133 131
15. Watson AJ, Smith BB, Whitehead MR, et al.: Malignant
progression of anal intra-epithelial neoplasia. ANZ J Surg 2006,
76:715–717.
16. Scholefield JH, Castle MT, Watson NF: Malignant transformation
of high-grade anal intraepithelial neoplasia. Br J Surg 2005,
92:1133–1136.
17. Palefsky JM, Holly EA, Ralston ML, et al.: Effect of highly
active antiretroviral therapy on the natural history of anal
squamous intraepithelial lesions and anal human papillomavi-
rus infection. J Acquir Immune Defic Syndr 2001, 28:422–
428.
18. Engels EA, Biggar RJ, Hall HI, et al.: Cancer risk in people
infected with human immunodeficiency virus in the United States.
Int J Cancer 2008, 123:187–194.
19. van der Helm JJ, Hoebe CJ, van Rooijen MS, et al.: High
performance and acceptability of self-collected rectal swabs for
diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in
men who have sex with men and women. Sex Transm Dis 2009,
36:493–497.
20. Cranston RD, Darragh TM, Holly EA, et al.: Self-collected versus
clinician-collected anal cytology specimens to diagnose anal
intraepithelial neoplasia in HIV-positive men. J Acquir Immune
Defic Syndr 2004, 36:915–920.
21. Darragh TM, Jay N, Tupkelewicz BA, et al.: Comparison of
conventional cytologic smears and ThinPrep preparations from the
anal canal. Acta Cytologica 1997, 41:1167–1170.
22. Solomon D, Davey D, Kurman R, et al.: The 2001 Bethesda
System: terminology for reporting results of cervical cytology.
JAMA 2002, 287:2114–2119.
23. Panther LA, Wagner K, Proper J, et al.: High-resolution anoscopy
findings for men who have sex with men: inaccuracy of anal
cytology as a predictor of histologic high-grade anal intraepithelial
neoplasia and the impact of HIV serostatus. Clin Infect Dis 2004,
38:1490–1492.
24. Chiao EY, Giordano TP, Palefsky JM, et al.: Screening HIV-
infected individuals for anal cancer precursor lesions: a systematic
review. Clin Infect Dis 2006, 43:223–233.
25. • Berry JM, Palefsky JM, Jay N, et al.: Performance characteristics
of anal cytology and human papillomavirus testing in patients
with high-resolution anoscopy-guided biopsy of high-grade anal
intraepithelial neoplasia. Dis Colon Rectum 2009, 52:239–247.
This study describes the sensitivity of abnormal anal cytology to
detect HGAIN. Sensitivity was 87% in HIV-positive men and 55%
in HIV-negative men.
26. Palefsky JM, Holly EA, Hogeboom CJ, et al.: Anal cytology as a
screening tool for anal squamous intraepithelial lesions. J Acquir
Immune Defic Syndr Hum Retrovirol 1997, 14:415–422.
27. Goldstone SE, Enyinna CS, Davis TW: Detection of oncogenic
human papillomavirus and other predictors of anal high-grade
dysplasia in men who have sex with men with abnormal cytology.
Dis Colon Rectum 2009, 52:31–39.
28. •• Kaplan JE, Benson C, Holmes KH, et al.: Guidelines for
prevention and treatment of opportunistic infections in HIV-
infected adults and adolescents: recommendations from CDC, the
National Institutes of Health, and the HIV Medicine Association
of the Infectious Diseases Society of America. MMWR Recomm
Rep 2009, 58(RR-4):1–207. This article presents the guidelines
from the US Public Health Service for screening and treatment of
AIN in HIV-positive individuals.
29. Goldie SJ, Kuntz KM, Weinstein MC, et al.: The clinical
effectiveness and cost-effectiveness of screening for anal squa-
mous intraepithelial lesions in homosexual and bisexual HIV-
positive men. JAMA 1999, 281:1822–1829.
30. Goldie SJ, Kuntz KM, Weinstein MC, et al.: Cost-effectiveness of
screening for anal squamous intraepithelial lesions and anal cancer
in human immunodeficiency virus-negative homosexual and
bisexual men. Am J Med 2000, 108:634–641.
31. Karnon J, Jones R, Czoski-Murray C, Smith KJ: Cost-utility
analysis of screening high-risk groups for anal cancer. J Public
Health (Oxf) 2008, 30:293–304.
32. Jay N, Berry JM, Darragh T, .Palefsky JM: Abstract P19.16:
Treatment of diffuse high-grade anal intraepithelial neoplasia with
5% fluorouracil cream. Presented at the 25th International
Papillomavirus Conference. Malmo, Sweden; 2009.
33. •• Pineda CE, Berry JM, Jay N, et al.: High-resolution anoscopy
targeted surgical destruction of anal high-grade squamous intra-
epithelial lesions: a ten-year experience. Dis Colon Rectum 2008,
51:829–835. This article describes a retrospective study of
patients treated for HGAIN using surgery guided by HRA,
followed by office-based procedures to treat recurrent disease.
After 36 months of follow-up, HGAIN had a high resolution rate
(86%) with a low complication rate.
34. • Singh JC, Kuohung V, Palefsky JM: Efficacy of trichloroacetic
acid in the treatment of anal intraepithelial neoplasia in HIV-
positive and HIV-negative men who have sex with men. J Acquir
Immune Defic Syndr 2009, 52:474–479. This retrospective study
of 35 HIV-positive and 19 HIV-negative MSM demonstrated
efficacy of 85% trichloroacetic acid in the treatment of AIN. On a
per lesion basis, 71% of HGAIN lesions cleared to either LGAIN
or no lesion; in HIV-positive MSM, those with two or fewer
lesions had the highest rate of clearance.
35. Wieland U, Brockmeyer NH, Weissenborn SJ, et al.: Imiquimod
treatment of anal intraepithelial neoplasia in HIV-positive men.
Arch Dermatol 2006, 142:1438–44.
36. • Kreuter A, Potthoff A, Brockmeyer NH, et al.: Imiquimod leads
to a decrease of human papillomavirus DNA and to a sustained
clearance of anal intraepithelial neoplasia in HIV-infected men. J
Invest Dermatol 2008, 128:2078–83. This open label-study of 17
patients treated with imiquimod for AIN demonstrated a 74%
clearance of the original lesion; however, more than half of
patients developed new lesions during follow-up.
37. Goldstone SE, Hundert JS, Huyett JW: Infrared coagulator
ablation of high-grade anal squamous intraepithelial lesions in
HIV-negative males who have sex with males. Dis Colon Rectum
2007, 50:565–75.
38. • Stier EA, Goldstone SE, Berry JM, et al.: Infrared
coagulator treatment of high-grade anal dysplasia in HIV-
infected individuals: an AIDS malignancy consortium pilot
study. J Acquir Immune Defic Syndr 2008, 47:56–61. This
small, multicenter, phase 1 study demonstrated that infrared
coagulator treatment of HGAIN in HIV-positive individuals
was well tolerated, with resolution of 64% of lesions after
treatment.
39. Cranston RD, Hirschowitz SL, Cortina G, Moe AA: A
retrospective clinical study of the treatment of high-grade
anal dysplasia by infrared coagulation in a population of HIV-
positive men who have sex with men. Int J STD AIDS 2008,
19:118–120.
40. Nathan M, Hickey N, Mayuranathan L, Vowler SL, Singh N:
Treatment of anal human papillomavirus-associated disease: a
long term outcome study. Int J STD AIDS 2008, 19:445–9.
41. Guiliano A, Palefsky J: Abstract O-01.07: Quadrivalent HPV
Vaccine Efficacy Against Male Genital Disease And Infection.
25th International Papillomavirus Conference. Malmo, Sweden,
2009.
42. Ault KA: Effect of prophylactic human papillomavirus L1
virus-like-particle vaccine on risk of cervical intraepithelial
neoplasia grade 2, grade 3, and adenocarcinoma in situ: a
combined analysis of four randomised clinical trials. Lancet 2007,
369:1861–8.
132 Curr Infect Dis Rep (2010) 12:126–133
43. Kim JJ, Goldie SJ: Cost effectiveness analysis of including boys
in a human papillomavirus vaccination programme in the United
States. BMJ 2009, 339:b3884.
44. Centers for Disease Control and Prevention: National, state, and
local area vaccination coverage among adolescents aged 13–
17 years—United States, 2008. MMWR Morb Mortal Wkly Rep
2009, 58:997–1001.
45. • Chin-Hong PV, Husnik M, Cranston RD, et al.: Anal human
papillomavirus infection is associated with HIV acquisition in men
who have sex with men. AIDS 2009, 23: 1135–42. This
prospective cohort study of HIV-negative MSM demonstrated that
infection with two or more types of anal HPV was independently
associated with acquisition of HIV after adjustment for demo-
graphic and other risk factors.
46. Sexton J, Garnett G, Rottingen JA: Metaanalysis and metare-
gression in interpreting study variability in the impact of sexually
transmitted diseases on susceptibility to HIV infection. Sex
Transm Dis 2005, 32:351–7.
Curr Infect Dis Rep (2010) 12:126–133 133
